Additional file 6: Table S3. of Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
收藏NIAID Data Ecosystem2026-03-09 收录
数据链接：
官方服务：
资源简介：
Anti-GAB2 IP of Axitinib vs DMSO treated cells. SILAC ratios are normalized to GAB2 and log2 transformed. Significant affected proteins are determined using Significance A (MaxQuant, p < 0.05, BH corrected). Proteins are shortlisted if minimally one IP exhibited a significant regulation and the other IP showed the same trend (see Additional file 2: Figure S2). PEP: posterior error probability. (XLSX 185 kb)
创建时间：
2016-12-15
